Implementation of a Rapid Recovery Program in Gynecologic Oncology Surgery: A Pilot Study
Early Phase 1
Completed
- Conditions
- Cervical CancerUterine Endometrial CancerOvarian Cancer
- Interventions
- Procedure: LaparotomyDrug: intravenous narcoticsDrug: regional anesthesiaDrug: standard anesthesiaDrug: Non-steroidal anti-inflammatory drugs
- First Posted Date
- 2012-10-12
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 103
- Registration Number
- NCT01705288
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Busulfan and Cyclophosphamide Followed By ALLO BMT
Not Applicable
Terminated
- Conditions
- Myelodysplastic SyndromeAcute Lymphoblastic LeukemiaAcute Myeloid Leukemia
- Interventions
- Biological: Allogeneic hematopoietic stem cell transplantBiological: FilgrastimBiological: antithymocyte globulin
- First Posted Date
- 2012-09-14
- Last Posted Date
- 2021-04-13
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 5
- Registration Number
- NCT01685411
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute Leukemia
Phase 2
Withdrawn
- Conditions
- Acute Myeloid LeukemiaAcute Lymphoblastic Leukemia
- Interventions
- Biological: allogeneic hematopoietic cell transplantation
- First Posted Date
- 2012-09-03
- Last Posted Date
- 2017-12-02
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Registration Number
- NCT01677949
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
Not Applicable
Recruiting
- Conditions
- ImmunodeficienciesHemoglobinopathiesHematologic Disorders
- Interventions
- Radiation: Total body irradiationBiological: Stem cell transplant
- First Posted Date
- 2012-08-16
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 30
- Registration Number
- NCT01666080
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
Not Applicable
Recruiting
- Conditions
- Omenn's SyndromeWiskott-Aldrich SyndromeBare Lymphocyte SyndromeSCIDHemophagocytic LymphohistiocytosisLangerhan's Cell HistiocytosisReticular DysgenesisCommon Variable ImmunodeficiencyHyper IgM SyndromeGriscelli Syndrome
- Interventions
- First Posted Date
- 2012-07-27
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 30
- Registration Number
- NCT01652092
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploid Donor Natural Killer Cell Treatment in Older AML in First Complete Remission
Phase 2
Withdrawn
- Conditions
- Acute Myelogenous Leukemia
- Interventions
- Biological: CD3-/CD19- natural killer cellsBiological: CD3-CD56+ natural killer cellsDevice: CliniMACS® CD3 and CD19 Reagent SystemDevice: CliniMACS® CD56 Reagent System
- First Posted Date
- 2012-07-12
- Last Posted Date
- 2017-12-02
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Registration Number
- NCT01639456
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation
Phase 1
Completed
- Conditions
- Multiple MyelomaAcute Myelogenous LeukemiaChronic Myelogenous LeukemiaMyelodysplastic SyndromeAcute Lymphocytic LeukemiaHodgkin LymphomaNon-Hodgkin LymphomaChronic Lymphocytic Leukemia
- Interventions
- Biological: iTreg
- First Posted Date
- 2012-07-06
- Last Posted Date
- 2019-01-18
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 16
- Registration Number
- NCT01634217
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Reduced-Intensity Hematopoietic Stem Cell Transplant for High Risk Lysosomal and Peroxisomal Disorders
Not Applicable
Completed
- Conditions
- Lysosomal Storage DiseasePeroxisomal Disorder
- Interventions
- Radiation: Total Body Irradiation with Marrow BoostingBiological: Hematopoietic stem cell transplantation
- First Posted Date
- 2012-06-22
- Last Posted Date
- 2017-12-05
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 3
- Registration Number
- NCT01626092
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Cancer and Mindfulness-Based Cancer Recovery After Chemotherapy
Not Applicable
Completed
- Conditions
- Breast CancerOvarian CancerColorectal CancerUterine Cancer
- Interventions
- Behavioral: Mindfulness Based Cancer Recovery
- First Posted Date
- 2012-05-18
- Last Posted Date
- 2017-12-02
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 45
- Registration Number
- NCT01601548
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Empowering Cancer Survivors Through Information Technology
Not Applicable
Completed
- Conditions
- Cancer Survivor
- Interventions
- Behavioral: UMFollowUpOther: Standard of Care
- First Posted Date
- 2012-05-08
- Last Posted Date
- 2017-12-02
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 53
- Registration Number
- NCT01593618
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
© Copyright 2025. All Rights Reserved by MedPath